Avai Bio (AVAI) Net Equity Issued and Repurchased (2023 - 2026)

Avai Bio has disclosed Net Equity Issued and Repurchased across 4 years of filings, most recently posting $705.0 for Q2 2026.

• In Q2 2026, Net Equity Issued and Repurchased rose 376.35% year-over-year to $705.0; the TTM figure through Jun 2026 stood at $16405.0 (down 19.95% YoY), while the FY2026 annual figure was $15848.0, down 21.53% from the prior year.
• Net Equity Issued and Repurchased came in at $705.0 for Q2 2026 at Avai Bio, down from $15180.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $32374.0 in Q1 2024 to a low of -$150.0 in Q2 2024.
• Average Net Equity Issued and Repurchased over 4 years is $8691.9, with a median of $5766.0 recorded in 2023.
• Year-over-year, Net Equity Issued and Repurchased slumped 100.58% in 2024 and soared 6443.1% in 2026.
• Over 4 years, Net Equity Issued and Repurchased stood at $10527.0 in 2023, then slumped by 50.04% to $5259.0 in 2024, then tumbled by 96.16% to $202.0 in 2025, then soared by 249.01% to $705.0 in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $705.0 in Q2 2026, $15180.0 in Q1 2026, and $202.0 in Q4 2025.